Nationally recognized gastroenterologist joins NYU Langone to lead pediatric IBD program

Nationally recognized gastroenterologist joins NYU Langone to lead pediatric IBD program

Nationally recognized pediatric gastroenterologist Michael Dolinger, MD, MBA, joins Hassenfeld Children's Hospital at NYU Langone as director of the Inflammatory Bowel Disease Program in Pediatric Gastroenterology. Dr. Dolinger is also an assistant professor in the Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology at the NYU Grossman School of Medicine and brings extensive expertise in innovative diagnostic and treatment approaches to improve the care of children with inflammatory bowel disease (IBD), including Crohn's disease and peptic ulcer disease, and colitis-colitis-colitis-colitis.

One of the most important contributions of Dr. Dolinger's field work is his pioneering use of intestinal ultrasound as a real-time, noninvasive tool to assess disease activity. After training in Europe, he became the first U.S. gastroenterologist certified in bedside intestinal ultrasound and managed the way IBD is monitored and managed. To further this innovation, he co-founded the Intestinal Ultrasound Group of the United States and Canada (IUSCAN), an organization dedicated to training clinicians throughout North America in this advanced technique.

I have always been driven by the desire to make a real difference in the lives of children with IBD. The opportunity to lead the pediatric IBD program at Hassenfeld Children's Hospital is a chance to expand access to groundbreaking, non-invasive diagnostic techniques such as intestinal ultrasound. Our goal is to prioritize the best outcomes for every patient and family and ensure they receive the highest quality care in a supportive and compassionate environment. “

Dr. Michael Dolinger, MD, MBA

Dr. Dolinger will see patients at Fink Children's Ambulatory Care Center and NYU Langone's Inflammatory Bowel Disease Center, which takes a holistic approach to IBD management. The center integrates the latest medical and surgical therapies with nutritional support, psychological care and a strong emphasis on shared decision-making with patients and their families. Additionally, it will provide a seamless transition for young patients as they move from pediatric to adult care, helping them maintain continuity of care.

"Dr. Dolinger's extensive expertise in both the clinical and research aspects of IBD will significantly improve our ability to serve children suffering from these chronic diseases," said David P. Hudesman, MD, director of the Inflammatory Bowel Disease Center. “His innovative approach to diagnostics and patient care aligns perfectly with our commitment to providing the most advanced, patient-centered treatments.”

Children with IBD face different challenges, including impaired growth and puberty due to chronic inflammation. The disease can also impact diet, school attendance, mental health, and overall quality of life, requiring a comprehensive, multidisciplinary approach that goes beyond medication. Dr. Dolinger's clinical expertise and leadership is combined with dedicated support thanks to the Sala Institute for Child and Family Centered Care, which offers specialized services such as certified child life specialists, social workers and other family-focused services to create a premier care experience for children, youth and their families. After the guidance of Dr. According to Dolinger, the program will expand access to cutting-edge diagnostics and develop personalized treatment strategies tailored to the unique needs of children and adolescents with IBD.

"Dr. Dolinger's arrival is a transformative step in our ongoing commitment to providing compassionate, family-centered pediatric gastroenterology and IBD care care," said Nadia Ovchinsky, MD, director of the Division of Pediatric Gastroenterology and Hepatology in the Division of Pediatrics. “We are thrilled that with his leadership, the Pediatric Inflammatory Bowel Disease Program will not only advance advances in cutting-edge treatments, but also ensure a holistic approach to improving the lives of children and their families as they navigate these challenging conditions.”

About Dr. Dolinger

Aside from his clinical work, Dr. Dolinger actively participates in outcomes research and evaluates the effectiveness of real-world therapies to optimize treatment strategies. He is a member of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition IBD committee and has taught extensively at national and international conferences. His expertise is also reflected in his authorship of a recent article leading gastroenterologists in Crohn's diseaseThe Lanceta peer-reviewed medical journal.

Sources: